» Articles » PMID: 1704804

Selective Hypersensitivity to Granulocyte-macrophage Colony-stimulating Factor by Juvenile Chronic Myeloid Leukemia Hematopoietic Progenitors

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1991 Mar 1
PMID 1704804
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Juvenile chronic myelogenous leukemia (JCML) is a good model for the study of myeloproliferation because JCML hematopoietic progenitor cells grow in vitro at very low cell densities without the addition of exogenous stimulus. Previous studies have demonstrated that this proliferation is dependent on granulocyte-macrophage colony-stimulating factor (GM-CSF), and that removal of monocytes from the cell population before culture eliminates this "spontaneous" myeloproliferation, suggesting a paracrine role of monocyte stimulation. However, subsequent studies have shown that increased GM-CSF production from the JCML monocytes is not a consistent finding and therefore not a plausible sole mechanism. In examining hematopoietic growth factor dose-response curves, both JCML GM and erythroid nonadherent progenitor cell populations displayed a marked and selective hypersensitivity to GM-CSF. Responses to interleukin-3 and G-CSF were identical to control dose-response curves. This is the first demonstration of a myeloid leukemia in which hypersensitivity to a specific growth factor appears to be involved in the pathogenesis of the disease.

Citing Articles

Oncogenic and microenvironmental signals drive cell type specific apoptosis resistance in juvenile myelomonocytic leukemia.

Koleci N, Wu Y, Wehner N, Rajak J, Mittapalli V, Mergner J Cell Death Dis. 2025; 16(1):165.

PMID: 40057493 PMC: 11890777. DOI: 10.1038/s41419-025-07479-2.


Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.

Fu S, Guo Y, Peng Z, Zhang D, Chang Z, Xiao Y Med Oncol. 2024; 42(1):25.

PMID: 39652257 PMC: 11628578. DOI: 10.1007/s12032-024-02549-5.


Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia.

Zheng H, Zhao P, Tan Z, Yu W, Werner J, Stieglitz E Res Sq. 2024; .

PMID: 39149498 PMC: 11326406. DOI: 10.21203/rs.3.rs-4450642/v1.


Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.

Stieglitz E, Lee A, Angus S, Davis C, Barkauskas D, Hall D Cancer Discov. 2024; 14(9):1590-1598.

PMID: 38867349 PMC: 11374478. DOI: 10.1158/2159-8290.CD-23-1376.


LNK/ as a novel driver in juvenile myelomonocytic leukemia.

Wintering A, Hecht A, Meyer J, Wong E, Hubner J, Abelson S Haematologica. 2023; 109(8):2533-2541.

PMID: 38152053 PMC: 11290546. DOI: 10.3324/haematol.2023.283776.